Bill117th CongressFiled Feb 11, 2022Health
H.R. 6710
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Feb 11, 2022)
This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.
The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.
What just happenedFeb 14, 2022
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Herrell, Yvette [R-NM-2](R-NM)Sponsor
20 cosponsors20 R
20cosponsors1committees4actions1related bills6subjects
- Introduced in HouseFeb 11, 2022
- Feb 14, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Feb 11, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Feb 11, 2022IntroReferralIntro-H
Introduced in House
- Feb 11, 2022IntroReferral1000
Introduced in House